TORONTO, Aug. 25 /CNW/ - Lorus Therapeutics Inc. ("Lorus"), a
biopharmaceutical company specializing in the research and development of
pharmaceutical products and technologies for the management of cancer, today
announced that further to its previously announced transaction with High Tech
Beteiligungen GmbH & Co. KG to issue 28.8 million common shares at $0.36 per
share for gross proceeds of $10.4 million, it has successfully filed its final
prospectus qualifying the distribution of such shares. The offering is
scheduled to close by the end of August 2006.
